The Viral Transport Media is a new addition to the LaunchWorks suite of products and service offerings. As an FDA-registered ISO 13485 certified company, LaunchWorks is a division of Integreon Global, which has supported LaunchWorks’ expansion in molecular diagnostics with the additions of new service offerings, including embarking on an automation program designed to help its customers be more competitive. Recently, a significant portion of the company’s efforts have involved the response to the COVID-19 crisis, and the development of Viral Transfer Media is a valuable addition.
“We’re grateful to contribute to the fight against the pandemic, and to add this important component to our product portfolio,” said Jeff Kelly, general manager, LaunchWorks CDMO. “Our team has worked hard to bring this product to market, and the addition brings us one step closer to offering an end-to-end solution for our customers supporting the fight against COVID-19.
“This reinforces the LaunchWorks’ commitment to continue to expand and support the world’s changing needs due to the pandemic,” he continued. “The Launchworks service suite ranges from package design to formulation, filling, and fulfillment, making us uniquely positioned to help companies translate their science into commercial products. We take pride in our ability to contribute to the resulting improvement in world health.”